Skip to Content
Global News Select

Zoetis 2Q Livestock Products Sales Fall Amid Less Demand From Food-Service Sector — Commodity Comment

By Dave Sebastian

Zoetis Inc. on Thursday reported higher profit and overall U.S. revenue for the second quarter, though sales from its livestock products in the U.S. declined 18% as meatpackers faced supply-chain disruptions and the company received less demand from the food-service industry amid the Covid-19 pandemic.

"Producers are adjusting to new market demands and distribution needs--from food service and restaurant channels to more grocery and retail channels--while also managing ongoing labor, safety and trade issues," Chief Executive Kristin Peck said on a conference call. "As expected, U.S. livestock in the second quarter saw significant downturn as we expect that to remain a challenge for the rest of the year."

The Parsippany, N.J.-based company makes vaccines and medication for livestock and pets. Its U.S. revenue from pet products grew 6% as customers spent more time at home with their pets amid shelter-in-place measures, while overall sales were about flat from a year ago.

Livestock-product sales in China rebounded along with its Covid-19 recovery, Ms. Peck said. The company also is tracking how Latin American countries, such as Brazil, will perform for the remainder of the year, she added.

Write to Dave Sebastian at

(END) Dow Jones Newswires

August 06, 2020 13:15 ET (17:15 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.